Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

3.20USD
21 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.20
Open
$3.25
Day's High
$3.25
Day's Low
$3.15
Volume
1,818,445
Avg. Vol
1,036,933
52-wk High
$4.08
52-wk Low
$1.95

Chart for

About

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product... (more)

Overall

Beta: 2.95
Market Cap(Mil.): $145.22
Shares Outstanding(Mil.): 45.38
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Acelrx pharmaceuticals says co entered into 2nd amendment with Patheon Pharma

* Acelrx Pharmaceuticals - on August 22, co entered second amendment to manufacturing services deal effective as of august 4, 2017, with Patheon Pharma

Aug 23 2017

BRIEF-Acelrx Pharmaceuticals Q2 loss per share $0.29

* Acelrx Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

Aug 01 2017

BRIEF-AcelRx Pharmaceuticals reports successful outcome of Zalviso phase 3 IAP312 study on device functionality

* Acelrx Pharmaceuticals reports successful outcome of zalviso phase 3 IAP312 study on device functionality

Aug 01 2017

BRIEF-Acelrx Pharmaceuticals appoints Raffi Asadorian CFO

* Acelrx Pharmaceuticals appoints Raffi Asadorian as chief financial officer

Jul 19 2017

BRIEF-Acelrx Pharmaceuticals updates on notification from U.S. FDA

* U.S. FDA notified co that it no longer plans to hold an advisory committee meeting in connection with its review of NDA for Dsuvia

Jun 07 2017

BRIEF-Acelrx Pharmaceuticals files for mixed shelf of up to $150 mln

* Acelrx Pharmaceuticals Inc files for mixed shelf of up to $150.0 million - sec filing Source text - http://bit.ly/2ruEt7F Further company coverage:

Jun 05 2017

BRIEF-Acelrx Pharmaceuticals CFO Timothy Morris resigns

* Acelrx Pharmaceuticals - on June 2, CFO Timothy E. Morris notified co of his resignation from all positions with co effective immediately - SEC filing

Jun 05 2017

BRIEF-AcelRx Pharmaceuticals reports Q1 total revenue $3.1 million

* AcelRx Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

May 08 2017

BRIEF-AcelRx Pharma says DSUVIA resulted in 3-point reduction in pain intensity within 60 minutes of administration

* AcelRx Pharmaceuticals presenting comprehensive DSUVIA clinical trial results at ASRA's annual regional anesthesiology and acute pain medicine meeting

Apr 06 2017

BRIEF-European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil

* European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil 30 mcg tablet (ARX-04) for moderate-to-severe acute pain

Mar 28 2017

Earnings vs. Estimates